Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients

Código QR

Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients

Abstract Myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombosis and bleeding. Vitamin K antagonists (VKAs) are the historic anticoagulant recommended for use in MPNs. Direct oral anticoagulants (DOACs) are being increasingly used in general and cancer populations. H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joan How, Charlotte Story, Siyang Ren, Donna Neuberg, Rachel P. Rosovsky, Gabriela S. Hobbs, Jean M. Connors
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1bf298661bb7441685ae80d6e5b9f931
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Magdalena M. Brune, et al.
Publicado: (2021)

FREQUENCY OF TET2 GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
por: Syed Owais Ali, et al.
Publicado: (2021)

Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing
por: Arti Easwar, et al.
Publicado: (2021)

Use of direct oral anticoagulants does not significantly increase delayed bleeding after endoscopic submucosal dissection for early gastric neoplasms
por: Jinju Choi, et al.
Publicado: (2021)

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
por: Alessandro Lucchesi, et al.
Publicado: (2021)

Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants
por: Elena Sabattini, et al.
Publicado: (2021)

New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
por: Domenico Penna
Publicado: (2021)

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases
por: Marco Pizzi, et al.
Publicado: (2021)

A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms
por: Hua Wang, et al.
Publicado: (2017)

THE OUTCOME OF FATHERHOOD IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, A SINGLE INSTITUTION EXPERIENCE
por: Elrazi Ali, et al.
Publicado: (2021)

Direct Oral Anticoagulants Concentration Testing in Clinical Practice for High-Risk Patients with AF
por: K Pukite, et al.
Publicado: (2020)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hans C. Hasselbalch, et al.
Publicado: (2021)

Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
por: Juri Alessandro Giannotta, et al.
Publicado: (2021)

Direct Oral Anticoagulant (DOAC) to Warfarin Transitions in a Pharmacist-led Anticoagulation Clinic
por: Ashley G. Woodhouse, et al.
Publicado: (2019)

Direct oral anticoagulants; a review for the non-specialist
por: Thilina Gunawardena
Publicado: (2021)

Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?
por: Mahmoud Abdelnabi, et al.
Publicado: (2020)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Marko Lucijanic, et al.
Publicado: (2021)

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm
por: D. A. Casolari, et al.
Publicado: (2017)

Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms.
por: Mariana Selena Gonzalez, et al.
Publicado: (2014)

In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
por: Alessandra Balduini, et al.
Publicado: (2011)

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
por: Jinyong Kim, et al.
Publicado: (2021)

A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan
por: Cheng-Shyong Chang, et al.
Publicado: (2021)

Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
por: Gwang-Un Kim, et al.
Publicado: (2021)

A summary overview of the new, direct, target-specific oral anticoagulants
por: G. L. Muntingh
Publicado: (2016)

Low Dose of Direct Oral Anticoagulants after Left Atrial Appendage Occlusion
por: Pedro Luis Cepas-Guillen, et al.
Publicado: (2021)

Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants
por: Ji Yun Lee, et al.
Publicado: (2021)

High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.
por: Vittorio Rosti, et al.
Publicado: (2010)

Automated diagnostic support system with deep learning algorithms for distinction of Philadelphia chromosome-negative myeloproliferative neoplasms using peripheral blood specimen
por: Konobu Kimura, et al.
Publicado: (2021)

Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.
por: Joseph Saliba, et al.
Publicado: (2013)

Superior vena cava syndrome after pacemaker implantation treated with direct oral anticoagulation
por: Nicola Mumoli, et al.
Publicado: (2021)

Direct-Acting Oral Anticoagulants: A Resident-Based Workshop to Improve Knowledge and Confidence
por: Irsk Anderson, et al.
Publicado: (2020)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Daniele Cattaneo, et al.
Publicado: (2021)

Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
por: Begoña Navarro-Almenzar, et al.
Publicado: (2021)

Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance
por: Masarret Fazili, et al.
Publicado: (2020)

Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System
por: Masanobu Ishii, et al.
Publicado: (2017)

Direct-acting Anticoagulants in Chronic Coronary Syndromes
por: Emmanuel Sorbets, et al.
Publicado: (2020)

Use of anticoagulants in elderly patients: practical recommendations
por: Helia Robert-Ebadi, et al.
Publicado: (2009)

Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus.
por: Kazuhiko Kido, et al.
Publicado: (2021)

Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Clara Bonanad, et al.
Publicado: (2021)

Carotid Artery Stenting in Patients with Atrial Fibrillation: Direct Oral Anticoagulants, Brief Double Antiplatelets, and Testing Strategy
por: José E. Cohen, et al.
Publicado: (2021)